Histone deacetylase (HDAC) inhibitors such as panobinostat [152,153,154,155,156,157] have been tested in GBM in vitro and in vivo using the multiomics approach, showing some efficacy—especially when combined with other treatments. This evidence concerns the gene HDAC9 and glioblastoma.